CA3144557A1 - Prostate specific membrane antigen (psma) ligands and uses thereof - Google Patents

Prostate specific membrane antigen (psma) ligands and uses thereof Download PDF

Info

Publication number
CA3144557A1
CA3144557A1 CA3144557A CA3144557A CA3144557A1 CA 3144557 A1 CA3144557 A1 CA 3144557A1 CA 3144557 A CA3144557 A CA 3144557A CA 3144557 A CA3144557 A CA 3144557A CA 3144557 A1 CA3144557 A1 CA 3144557A1
Authority
CA
Canada
Prior art keywords
compound
formula
psma
group
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3144557A
Other languages
English (en)
French (fr)
Inventor
Maurizio F. MARIANI
Lorenza Fugazza
Daniela Chicco
Martin Gilbert Pomper
Sangeeta Ray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Accelerator Applications Italy SRL
Johns Hopkins University
Original Assignee
Advanced Accelerator Applications Italy SRL
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications Italy SRL, Johns Hopkins University filed Critical Advanced Accelerator Applications Italy SRL
Publication of CA3144557A1 publication Critical patent/CA3144557A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3144557A 2019-07-02 2020-06-30 Prostate specific membrane antigen (psma) ligands and uses thereof Pending CA3144557A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19184015.6 2019-07-02
EP19184015 2019-07-02
PCT/EP2020/068386 WO2021001360A1 (en) 2019-07-02 2020-06-30 Prostate specific membrane antigen (psma) ligands and uses thereof

Publications (1)

Publication Number Publication Date
CA3144557A1 true CA3144557A1 (en) 2021-01-07

Family

ID=67145647

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3144557A Pending CA3144557A1 (en) 2019-07-02 2020-06-30 Prostate specific membrane antigen (psma) ligands and uses thereof

Country Status (16)

Country Link
US (1) US20230226227A1 (enExample)
EP (1) EP3993837A1 (enExample)
JP (2) JP7805170B2 (enExample)
KR (1) KR20220044496A (enExample)
CN (3) CN120441497A (enExample)
AR (1) AR119331A1 (enExample)
AU (3) AU2020299974A1 (enExample)
BR (1) BR112021026812A2 (enExample)
CA (1) CA3144557A1 (enExample)
CL (1) CL2021003525A1 (enExample)
CO (1) CO2021017708A2 (enExample)
IL (1) IL289039A (enExample)
MX (1) MX2022000136A (enExample)
PH (1) PH12021553284A1 (enExample)
TW (1) TW202114742A (enExample)
WO (1) WO2021001360A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021219719A1 (en) * 2020-04-29 2021-11-04 Advanced Accelerator Applications (Italy) Srl Methods for radiolabelling psma binding ligands and their kits
CN121604981A (zh) 2023-07-21 2026-03-03 诺华公司 靶向psma的放射性配体治疗方案
WO2025125469A1 (en) 2023-12-13 2025-06-19 Swiss Rockets Ag Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271026A1 (en) 2000-07-11 2002-01-21 Bml, Inc. Remedies for bone diseases
HUE045028T2 (hu) * 2011-08-05 2019-12-30 Molecular Insight Pharm Inc Radiojelzett prosztataspecifikus membrán antigén inhibitorok
GEP20237479B (en) * 2013-10-18 2023-03-27 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
KR20250057132A (ko) 2016-03-22 2025-04-28 더 존스 홉킨스 유니버시티 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
US11478558B2 (en) * 2017-05-30 2022-10-25 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
IL276528B2 (en) * 2018-02-06 2024-11-01 Univ Johns Hopkins PSMA Targeted Radiohalogenated Urea-Polyaminocarboxylates For Cancer Radiotherapy
WO2020028323A1 (en) * 2018-07-30 2020-02-06 The Johns Hopkins Universtiy Competitive prostate-specific membrane antigen (psma) binding agents for the reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy

Also Published As

Publication number Publication date
PH12021553284A1 (en) 2022-08-01
JP2025165975A (ja) 2025-11-05
CO2021017708A2 (es) 2022-05-20
BR112021026812A2 (pt) 2022-02-22
CN120441497A (zh) 2025-08-08
WO2021001360A1 (en) 2021-01-07
EP3993837A1 (en) 2022-05-11
JP2022538478A (ja) 2022-09-02
MX2022000136A (es) 2022-04-27
AU2020299974A1 (en) 2022-01-27
AR119331A1 (es) 2021-12-09
TW202114742A (zh) 2021-04-16
US20230226227A1 (en) 2023-07-20
AU2024200850A1 (en) 2024-02-29
CN114341118A (zh) 2022-04-12
AU2024200850B2 (en) 2025-09-04
IL289039A (en) 2022-02-01
CN120441498A (zh) 2025-08-08
KR20220044496A (ko) 2022-04-08
AU2025271182A1 (en) 2025-12-18
JP7805170B2 (ja) 2026-01-23
CL2021003525A1 (es) 2022-10-21

Similar Documents

Publication Publication Date Title
JP6556805B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用
EP3209336B1 (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
KR102233726B1 (ko) 전립선 특이적 막 항원（psma)의 18f-태그된 저해제 및 전립선암에 대한 조영제로서 이의 용도
AU2024200850A1 (en) Prostate specific membrane antigen (psma) ligands and uses thereof
ligan et al. 99mTc-ethylenedicysteine-folate: a new tumor imaging agent. Synthesis, labeling and evaluation in animals
EP3856261A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
EP2862857A1 (en) Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP4474379A1 (en) Peptide urea derivative, pharmaceutical composition containing peptide urea derivative, and application of peptide urea derivative
EP4400505A1 (en) Peptide-urea derivative, pharmaceutical composition containing same and application thereof
Huangfu et al. PSMA and Sigma-1 receptor dual-targeted peptide mediates superior radionuclide imaging and therapy of prostate cancer
Moon et al. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting
EP3011976A1 (en) 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents
US20260007781A1 (en) Prostate specific membrane antigen (psma) ligands and uses thereof
KR20210102874A (ko) 방사성 표지된 gprp 길항제 및 계면활성제를 포함하는 약학적 조성물
Ertay et al. 99m Tc-exorphin C: A new peptide radiopharmaceutical for tumor imaging
KR20240115844A (ko) 암의 치료용 화합물 및 이의 조성물
JP2026506464A (ja) 部位特異的ｕＰＡＲ標的化のための放射性核種標識ペプチドコンジュゲート
CN120344273A (zh) 二聚体放射性药物、其组合物及其用途
KR20260040237A (ko) Psma 표적 방사성 리간드 치료 요법

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241028

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241028

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241030

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241227

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241227

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250118

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250118

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250319

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250708